.jpg?v=1681674245630)
"C+Correcting Complex 30%® is a do-it-all vitamin C [...] and can be used by a variety of skin types. The light weight formulation packs an antioxidant punch that brightens the skin and restores a more even, youthful skin surface." -Corey Hartman, MD
.jpg?v=1681675323526)
.jpg?v=1681675033132)
"The Revision Skincare® Purifying Cleansing Gel is another go-to salicylic acid cleanser. The super-concentrated formulation deeply cleans pores, removes oil, and impurities as lactic and salicylic acids exfoliate and clarify the skin." -Dr. Kathleen S.Viscusi
.jpg?v=1681675507346)
"When I am really good about using this product, and I'm using it daily for at least a month, I do see an improvement in my skin's quality overall. Most importantly, a peptide blend that is supposed to improve the skin firmness and elasticity and antioxidants and botanicals that will be anti-aging and help stave off the process of any further sagging." -Dr. Deirdre Hooper
.jpg?v=1681676460508)
"Intellishade® Matte by Revision Skincare® has SPF 45 and pore-minimizing technology to help reduce wrinkles, and improve complexion. The formula's game-changing peptide blend helps provide age-defying coverage. [...] aloe leaf and green tea extract work with the sheer mineral tint to increase moisturization. This moisturizer offers three different finishes to choose from: Original, Matte, and TruPhysical." Upon application, your skin will look firmer and more lifted, and your wrinkles will be concealed. In clinical studies, 94% of participants experienced more even-looking skin after using this product."
.jpg?v=1681676735251)
"[Nectifirm® Advanced] combats the visible signs of moderate to advanced aging on the neck and décolletage by utilizaing eight different peptides and Smart Antioxidant Technology." -Dr. Caroline Robinson "Help the skin appear more firm and lifted, reduce the appearance of rough and crepey skin and decrease the look of fine lines and wrinkles." -Dr. Hadley King
.jpg?v=1681677059047)
"Products that pair vitamin C with other antioxidants such as [...] or vitamin E, like Revision Skincare® C+ Correcting Complex, can enhance its effects" -Dr. Janiene Luke
.jpg?v=1681678151389)
"If brighter, clearer skin is your goal, then this Brightening Facial Wash by Revision Skincare is an instant add to cart. Brimming with Brightening ingredients, moisture boosters, [...] exfoliators, and protective antioxidants, this face wash formula is one of the best."
.jpg?v=1681677345933)
"This vitamin C serum contains a high concentration of THD Ascorbate, the most stable and lipid soluble form of vitamin C. It also includes antioxidants, such as vitamin E and Coenzyme Q10 and Squalane to moisturize and condition the skin."
.jpg?v=1681677545657)
"I love Revision Intellishade® Original because it is SPF 45, blends into most skin types, and can replace your makeup-it leaves the skin glowy and even." -Dr. Jennifer Segal
.jpg?v=1681678336324)
"This oil-free daily SPF is packed with anti-aging properties. With THD Ascorbate (vitamin C), green tea, pomegranate extract and hyaluronic acid, this product won't just protect your precious skin from the sun, but can also help improve the appearance of fine lines and wrinkles."
.jpg?v=1681678620426)
The signature iFirm™ technology is a collagen-boosting blend of peptides, antioxidants, botanical extracts, and prebiotics combined with glucosamine and caffeine to smoothen crepey skin and give you an all-over energized glow
"Revision Skincare’s derm-favorite Intellishade® gets a makeover with TruPhysical™ SPF 45, an all-mineral [sunscreen], still-invisible mix that protects skin while delivering a punch of [age-defying] peptides."
"On the heels of the launch of what seems like 20 new in-office body-sculpting devices this year comes a new crop of body products that go above and beyond hydration claims. Thanks to skin firming and cellulite-busting actives - caffeine, coffee extract and microalgaes, to name a few- these next-level lotions help maintain the results of high-tech energy treatments with no downtime."
“Peek inside the beauty cabinets of these women and you’ll see three unique skin-care routines with one common thread: a healthy, radiant glow” – Products used by Julie Russak, MD – “My tried-and-true philosophy is maintenance over full correction. From my experience, the best results are achieved with patience and a long-term commitment to a quality regimen."
"The skin on your neck deserves the same TLC you give your face. Revision Skincare® Nectifirm® ADVANCED utilizes peptides and antioxidants to smooth out wrinkles and crepey skin for a younger look."
"The end-all-be-all ingredient, this Vitamin A derivative does pretty much any and everything you can think of."
"D·E·J face cream® featured as Ciara’s skincare essential in the “Her Style” section of the April Issue."
“Don't forget your neck and décolletage"
.png?v=1681186014375)
“Revision Skincare’s Intellishade® gets an all-mineral makeover with TruPhysical™.”
.jpg?v=1681185995395)
"Our social-media generation is shining a spotlight on a trending ‘trouble area’: the jawline. [Marie Claire] examined the latest innovations that define, reshape and slenderize the lower face, sans scalpel … skincare products with peptides and damage-preventing antioxidants can help keep your chin up."
.jpg?v=1681185969210)
"Known for its ability to lighten [the appearance of] spots and leave skin with a dewy glow, this antioxidant-rich vitamin is a powerhouse for a better complexion."
"A wrinkle-free face is only half the battle when it comes to looking younger. Keep your neck smooth, too, with this peptide-rich cream that reduces [the appearance of] sagging and lines."
Lisa Holladay, Vice President and global brand leader for The Ritz-Carlton and St. Regis Hotels and Resorts logs over 200,000 air miles a year. "When the alarm goes off, I grab my phone to check emails for five minutes. I throw on my workout clothes, then give my fiancé a kiss and my dog a squeeze. I apply my Revision Skincare® sunscreen and head out to exercise."
"The formulation of Revision Skincare’s new Revox™ 7 serum is so lightweight, it almost feels like water. Each drop contains seven peptides to [reduce the appearance of] expression lines while softening skin imperfections."
"All skin types can benefit from this editor-favorite tinted moisturizer, which hydrates, smooths and protects skin from sun damage while leaving behind the most natural-looking hint of color."
"A powerful one-two punch of 30% stable Vitamin C and 0.5% time-released Retinol."
"Modeliste's go-to and A-List celebrity favorite, Dr. William Schweitzer at ProDerm Image Cosmetic Dermatology, gives us some tips and options for a quick non-surgical holiday season pick me up. "Dr. Schweitzer's Skincare Saver Recommendations: Revision Skincare Gentle Cleansing Lotion, Intellishade®, and Vitamin C Lotion."
"Reduce the appearance of fine lines and wrinkles with Revision Skincare’s moisturizing D.E.J face cream®. By containing key ingredients like Rosemary and Goji Fruit Extracts, the product also delivers an added kick of beneficial antioxidants!"
D·E·J Daily Boosting Serum™ transforms skin from tired and dull to luminous and glowing due to its unique formula.
For instant and lasting results, the D·E·J Daily Boosting Serum from Revision Skincare improves the visible effects of glycation on the skin with the brand's unique sunflower sprout extract technology.
Nature is healing. At least that's what Revision Skincare is counting on with its latest anti-aging product, DEJ Daily Boosting Serum. Made with exclusive sunflower sprout extract technology, the formula is designed to boost skin's cellular functions so it repairs and hydrates itself more rapidly.
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
(Dallas, Texas, Aug. 29, 2022) — Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis (low-lying lids) in adults.
This strategic partnership pairs two unique disruptors within the aesthetics and skincare industries, both focused on providing patients with high-quality results. With shared values and visions for business growth and an expanding footprint, the collaboration aligns two game-changing brands to offer more accessible solutions to aesthetic patients and providers nationwide.
For more than two decades, Revision Skincare® has been at the forefront of physician-dispensed brands. From pioneering the use of peptides to developing proprietary technologies and conducting novel ingredient research, this professional skincare brand creates clinically validated, high-potency products that protect, treat, and enhance the skin.
As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ.®
“We know that RVL Pharmaceuticals has a lot of choices when it comes to commercial partnerships. We are excited to join this mission with RVL to offer breakthrough patient solutions,” said Maria Carell, CEO, and President, Revision Skincare®.
Through the partnership, Revision Skincare® and RVL Pharmaceuticals will bring broader access to revolutionary innovations like D·E·J Eye Cream®, Revox™ Line Relaxer, and UPNEEQ®. The two companies plan to collaborate on a variety of marketing efforts within the medical aesthetics industry, working together to address significant unmet consumer needs.
“We are thrilled to partner with Revision Skincare®! Their strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics,” said Brian Markison, CEO, RVL Pharmaceuticals.
Revision Skincare® and RVL Pharmaceuticals have an unwavering commitment to innovation as consumers, patients, and health care partners look to them to provide solutions to their patients’ medical aesthetic needs. For more information, contact your local aesthetic skincare professional’s office.
About Revision Skincare®
Revision Skincare® is an industry leader in developing clinically-validated, high potency, transformative skincare products. Our unique formulation philosophy is an integrated approach that delivers maximum efficacy while maintaining long-term skin health. Based in Irving, Texas, Revision Skincare is sold in more than 16 countries.
About RVL Pharmaceuticals
RVL Pharmaceuticals is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. UPNEEQ is believed to be the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
IMPORTANT SAFETY INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ® were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
DRUG INTERACTIONS
Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.
Contact: Revision Skincare PR
Company: M Booth
Tel: (212) 481-7000
Email: revisionpr@mbooth.com
SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Gryphon Investors ("Gryphon"), a leading middle-market private equity firm, today announced that it has signed a definitive agreement to acquire Revision Skincare and Goodier Cosmetics (collectively "Revision Goodier"). In partnership with Revision Goodier's leadership team, including CEO Maria Carell, Gryphon will continue to invest in the company's mission of developing and delivering clinically-proven and highly-efficacious skincare products to a global customer base and advance the company's contract development and manufacturing ("CDMO") capabilities. Financial terms of the transaction were not disclosed. The transaction is expected to close in the fourth quarter of 2021.
For more than two decades, Revision Skincare® has provided dermatologists, plastic surgeons and medical spas with clinically proven, high-performing skincare products. Using only premium quality ingredients, the Revision Skincare collection was formulated to provide targeted solutions for enhancing skin's appearance and reducing signs of aging. Based in Irving, Texas, Revision Skincare is sold in more than 10 countries.
Since 1922, Irving, TX-based Goodier Cosmetics has been a trusted developer and manufacturer in cosmetic and OTC topical skincare solutions. Differentiated by an industry renowned Innovation Center of Excellence, Goodier, along with its team of R&D chemists, engineers and regulatory experts, remains at the forefront of market trends, new technologies, ingredients and advancements in formulation science.
Gryphon Operating Partner Mike Ferry said, "Revision has a unique position as a high-growth independent company in a compelling market. Skincare consumers are becoming more discerning about the products they use, and we are excited to invest in Revision's mission to help bring carefully formulated and highly efficacious skincare products to a global customer base."
Eddie Douglas, Principal in Gryphon's Consumer Group, noted, "We are thrilled to partner with Maria and her outstanding team to support Revision's movement to bring scientific credibility, quality, innovation, and elegance to the professional skincare market. We are equally excited about the opportunity to build on Goodier's differentiated capabilities and deliver world-class service to some of the fastest growing brands across the prestige beauty and personal care space."
Ms. Carell commented, "We are delighted to partner with the team at Gryphon as we enter our next phase of growth. Gryphon is an ideal partner given their knowledge of skincare, consumer health, and professionally-endorsed brands, and their investment will allow us to accelerate the incredible momentum we have built over the last few years."
Matt Farron, Partner and Head of Gryphon's Consumer Group, added, "Revision Goodier represents a bullseye opportunity for Gryphon and leverages our proactive focus of investing behind leading efficacious skincare brands. We are proud to be partnering with the Revision Goodier management team, leaders in the clinical, efficacious skincare category, and to be supporting the team through their next phase of growth."
Revision Goodier's management team will continue to be led by CEO Maria Carell. As part of the transaction, a number of Gryphon Executive Advisors will join Gryphon Operating Partner Mike Ferry, Gryphon Deal Partner Matt Farron, and Gryphon Principal Eddie Douglas on the Board of Directors. The transaction marks Gryphon's third investment in skincare products and services and first investment in the physician dispensed skincare category.
William Blair & Company, LLC is serving as the exclusive financial advisors to Gryphon. Financo Raymond James is serving as financial advisors to Revision Goodier. Kirkland & Ellis LLP is acting as legal advisor to Gryphon, and Sidley Austin LLP is acting as legal advisor to Revision Goodier.
Revision Skincare® ("Revision"): One of the first brands to be sold through doctors' offices, Revision Skincare® is known for its ground-breaking, effective and scientifically proven formulations, changing the way clinical skincare results are achieved. Revision offers products that are enabling patients and consumers to achieve beautiful skin without ever compromising the skin's long-term health. The portfolio includes well-known franchises such as Nectifirm®, Intellishade®, D·E·J and Revox™.
Goodier Cosmetics ("Goodier"): Goodier is a leading skincare CDMO with a long history of creating quality products with significant commercial success. Goodier is known for developing innovative formulations that utilize the latest ingredients and technologies, and for bringing products from concept to a saleable finished good. Customers, including high-growth emerging brands and established market-leading brands, turn to Goodier for its flexible customer-centric service and full turn-key experience. Goodier stands out as one of the preferred CDMOs specializing in high-end topical solutions.
About Gryphon Investors
Based in San Francisco, Gryphon Investors (www.gryphoninvestors.com) is a leading private equity firm focused on profitably growing and competitively enhancing middle-market companies in partnership with experienced management. The firm has managed over $7.5 billion of equity investments and capital since 1997. Gryphon targets making equity investments of $50 million to $300 million in portfolio companies with enterprise values ranging from approximately $100 million to $600 million. Gryphon prioritizes investment opportunities where it can form strong partnerships with owners and executives to build leading companies, utilizing Gryphon's capital, specialized professional resources, and operational expertise.
Contact:
Lambert & Co.
Caroline Luz
203-656-2829
cluz@lambert.com
or
Jennifer Hurson
845-507-0571
jhurson@lambert.com
SOURCE Gryphon Investors
Related Links
https://www.gryphon-inv.com
April 21, 2022
Revision Skincare is pleased to announce the promotion of Chris Murray to the newly created position of Vice President of Strategic Partnerships. Over his 16-year career, Chris has successfully built a national network of providers and industry contacts. Chris’s vast experience in growing partnerships, connecting customers across the country, and developing new and unique opportunities to grow the overall aesthetics industry will serve him well in this position.
With the addition of this new role, Revision Skincare further solidifies itself in the Physician Dispensed Skincare market by creating a position centered around two of our core values, Relentless Innovation and Collaboration. We believe that strong relationships and partnerships, along with our industry business partners, and especially with our customers, is critical to the organization’s continued success. The development and launch of Revox Line Relaxer as a procedural pairing product was an example of this approach. We are helping our providers give their patients the best possible outcome, while adding an area of the face to drive revenue in the practice.
“We have a tremendous opportunity to help improve patient outcomes in the aesthetic space, by partnering with our fellow industry colleagues and companies to further aesthetic outcomes, and ultimately leading to the overall growth of this space,” says Maria Carell, Revision Skincare CEO.
News Release
Contact: Revision Skincare PR
Company: M Booth
Tel: (212) 481-7000
Email: revisionpr@mbooth.com
For Immediate Release
ABSTRACT
Background: Extrinsic factors including solar radiation and air pollution significantly impact facial skin aging. The efficacy and tolerability of a 2-step skincare regimen consisting of a vitamin C antioxidant serum (VCAS) and a 100% mineral tinted sunscreen moisturizer (TSM) were evaluated in women with hyperpigmented and photodamaged facial skin exposed to beach, mountain, and river-traversed basin city stressors.
Methods: This was an institutional review board (IRB)-approved, multi-center, prospective, open-label study involving healthy subjects. Thirty-six females aged 35 to 60 years with Fitzpatrick Skin Types I to V and exhibiting moderate to severe hyperpigmentation and moderate photodamage were recruited. The VCAS was applied to the global face twice-daily (morning and evening), and the TSM was applied in the morning with at least 2 reapplications during daily activity for 12 weeks. Clinical grading with a validated scale, standardized photography, and a self-assessment questionnaire were performed at baseline and weeks 4, 8, and 12.
Results: Statistically significant improvements were shown in clinically graded efficacy parameters at weeks 4, 8, and 12. Subjects showed an average improvement of 11.7%, 14.9%, and 19.1% in overall photodamage and an average improvement of 19.5%, 23.4%, and 24.5% in clarity/brightness at weeks 4, 8, and 12, respectively. Forehead lines and cheek lines demonstrated clinically significant improvement from baseline to week 12. Both products were well-tolerated and well-perceived by subjects.
Conclusion: The 2-step skincare regimen was well-tolerated and effective in improving extrinsic signs of facial aging induced by solar radiation and air pollution stressors after 12 weeks of use.
J Drugs Dermatol. 2023;22(1):16-22. doi:10.36849/JDD.7154
Citation: Cohen J, Palm M, Biesman B, et al. Two-step skincare regimen addressing aging in three unique geographic locations: A prospective, multi-center, open-label study. J Drugs Dermatol. 2023 Jan 1;22(1):16-22. doi: 10.36849/JDD.7154.
To assess the effect of a 28-day skincare regimen in healthy female subjects on the facial skin microbiome composition and to determine whether the skincare regimen including a gentle cleansing lotion, a multi-functional anti-aging moisturizer formulated with prebiotics and postbiotics at skin neutral pH, and bland sunscreen pushed the microbiome to a healthier state and improved skin aging measured by self-assessment and clinical photography.
The study protocol was in accordance with the EU Scientific Committee on Consumer Safety (SCCS) guidance and met all international standards. In all, 25 female subjects between 35 and 65 years old with Fitzpatrick skin types I–VI, moderate crow's feet wrinkles and global face photodamage were enrolled. After 28 days, the skincare regimen improved microbial facial diversity and shifted the microbiota composition when compared to baseline.
After 28 days, the skincare regimen treatment shifted the distribution of the facial skin microbiome, positively influencing the skin microbiome diversity and balance, to promote long-term skin health and protect from further skin aging.
These results suggest that incorporating prebiotics and postbiotics into a skincare regimen may have a positive impact on the facial skin microbiome in healthy women.
A 12-week open-label, single-center clinical usage trial was conducted to determine the effectiveness of a dual product regimen consisting of a 0.5% retinol treatment and an anti-aging moisturizer with 30% vitamin C in women with mild to moderate hyperpigmented and photodamaged facial skin. Clinical grading of several efficacy parameters, tolerability evaluations, subject self-assessment questionnaires, and digital photography were completed at baseline and at weeks 4, 8, and 12. A total of 44 women completed the study. Effective ingredients incorporated into the 0.5% retinol treatment included encapsulated retinol for a retinol concentration of 0.5%, bakuchiol, and Ophiopogon japonicus root extract. The anti-aging moisturizer with 30% vitamin C contained 30% vitamin C in the form of tetrahexyldecyl ascorbate (THD ascorbate), alpha-tocopheryl acetate (vitamin E) and ubiquinone (coenzyme Q10). The facial regimen produced a statistically significant decrease (improvement) in clinical grading scores for all parameters assessed at weeks 8 and 12 when compared with baseline scores. In addition, the majority of these parameters were improved at week 4. The test regimen was well-perceived by the subjects for various inquiries regarding facial skin condition, product efficacy, and product attributes. Several tolerability parameters were assessed with no statistically significant increase except for dryness. A statistically significant increase in clinical grading scores for dryness on the face occurred at weeks 4 and 8 when compared to baseline scores. The increase in dryness is expected when introducing a retinol product to a facial regimen and the dryness did not persist to the week 12 time point.
J Drugs Dermatol. 2016;15(4):476-482.
THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE.
PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN.
NO PURCHASE NECESSARY.
PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
A 14-week single-center clinical usage study was conducted to test the efficacy of a peptide treatment serum and supporting skincare regimen in 29 women with mild to moderately photodamaged facial skin. The peptide treatment serum contained gamma-aminobutyric acid (GABA) and various peptides with neurotransmitter inhibiting and cell signaling properties. It was hypothesized that the peptide treatment serum would ameliorate eye and facial expression lines including crow’s feet and forehead lines. The efficacy of the supporting skincare regimen was also evaluated. An expert investigator examined the subjects at rest and at maximum smile. Additionally, the subjects completed self-assessment questionnaires. At week 14, the expert investigator found a statistically significant improvement in facial lines, facial wrinkles, eye lines, and eye wrinkles at rest when compared to baseline results. The expert investigator also found statistically significant improvement at week 14 in facial lines, eye lines, and eye wrinkles when compared to baseline results at maximum smile. In addition, there was continued highly statistically significant improvement in smoothness, softness, firmness, radiance, luminosity, and overall appearance at rest when compared to baseline results at the 14-week time point. The test regimen was well perceived by the subjects for efficacy and product attributes. The products were well tolerated with no adverse events.
J Drugs Dermatol. 2016;15(9):1100-1106.
THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE.
PLEASE SCROLL DOWN TO ACCESS THE FULL TEXT OF THIS ARTICLE WITHOUT LOGGING IN.
NO PURCHASE NECESSARY.
PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
Skincare cosmeceutical products have been shown to address intrinsic and extrinsic skin aging. Radiofrequency (RF) with microneedling is effective and safe in improving skin laxity and texture. Pairing skincare cosmeceutical products pre- and post-procedure is beneficial as it enhances patient results, patient results, patient experience, and reduces patient downtime.
To evaluate the tolerability, safety, and efficacy of a multi-ingredient anti-aging facial moisturizer when applied pre- and post-procedure consisting of a single RF microneedling treatment.
Fifteen female patients, aged 37-60, Fitzpatrick skin types I-IV, with mild-to-moderate wrinkles were included in the study. Patients applied a multi-ingredient anti-aging facial moisturizer twice a day (morning and night) two weeks prior to RF microneedling and four weeks post-RF microneedling (twice a day). At each time point, investigator objective assessment, self-assessments, and clinical photography were taken.
There were no adverse events as evaluated by the investigator. For this combined treatment and procedure patient scored comfort as the highest for satisfaction. Tolerability parameters erythema and edema were reported after RF microneedling treatment and were significant compared to the pre-procedure timepoint. Eighty percent of patients showed an improvement in Glogau Wrinkle Scale, but improvement was not statistically significant between baseline and end of study. Improvements in all skin attributes (radiance, tone, smoothness, texture, redness, dryness, and overall appearance) were statistically significant at the end of the study. Self-perceived skin attribute improvements included overall improvement, brightness, texture, pigmentation, redness, and tightness. The combination of the anti-aging facial moisturizer and RF microneedling was recommended by the patients in this study.
This clinical study positively supports the hypothesis that combining the multi-ingredient anti-aging facial moisturizer pre- and post-RF microneedling was safe and tolerable for the patients.
Melasma is a chronic pigmentary condition that can have significant negative effects on quality of life. Vitamin C can be effective in the treatment melasma, but its delivery often proves to be challenging due to instability of the drug and subsequent cutaneous irritation at higher concentrations.
In this prospective, open-label, evaluator-blinded study, we aimed to assess the efficacy and tolerability of twice-daily application of a novel, highly potent, non-irritating 30% tetrahexyldecyl (THD) ascorbate serum in combination with 100% mineral-based sunscreen in the treatment of melasma during the summer months.
Ten female subjects of ages ranging from 18 to 60 years underwent twice-daily application of 30% THD ascorbate serum in combination with an anti-aging 100% mineral tinted broad-spectrum protection SPF 45 sunscreen moisturizer for 12 weeks during the summer months (July to September). Two blinded evaluators scored baseline and post-treatment photographs using the Griffiths’ 10-point scale and global aesthetic improvement scale.
All subjects showed an improvement in hyperpigmentation with an average improvement of 33.7%. Seventy percent of subjects showed an improvement in skin tone evenness (redness), and among those subjects, the average improvement was 33.3%. The median global aesthetic improvement score was 2.0 (very much improved).
Our study demonstrated efficacy and safety in treating the pigmentary as well as vascular components of melasma with a novel 30% THD ascorbate serum and a purely mineral-based tinted moisturizing sunscreen.
Aging of upper arm skin, induced by intrinsic and extrinsic factors, often results in a loss of contour, elasticity, and firmness, and an increase in laxity, crepiness, roughness, and photodamage. A topical body firming moisturizer (TBFM) was developed to target all aspects of skin aging.
The aim of this study was to evaluate the efficacy and tolerability of the TBFM for upper arm firming and rejuvenation.
Forty female subjects, 40 to 60 years old, Fitzpatrick skin type II to V, with mild to moderate laxity, crepiness, and photodamage on the upper arms, were recruited into the study, 10 of whom were selected for biopsy analysis. Subjects were randomly allocated to apply the TBFM and placebo moisturizer on the assigned arms twice daily for 12 weeks. At each visit, efficacy and tolerability evaluation, self-assessment, and standardized clinical photography were performed. Ultrasound measurements were performed at baseline, week 8 and week 12.
Efficacy evaluation by a clinical grader and bioinstrumentation analysis showed the TBFM improved all skin parameters of the aged upper arm while outperforming the placebo moisturizer after 12 weeks. Clinical photography showed the test product toned and firmed the skin. The TBFM was well tolerated and well perceived by the subjects. Ultrasound images indicated an improvement in skin density and skin structure at week 12.
This clinical trial indicates that the TBFM was well tolerated and was effective in improving crepey, lax, and photodamaged skin of the upper arms after 12 weeks of treatment twice daily.
Objective: The dermal-epidermal junction (DEJ), composed of rare proteins, plays a significant role in facial skin aging. A newly enhanced multi-ingredient anti-aging facial moisturizer (MFM) and eye cream (MEC) were formulated to target DEJ-related aging. The objective of this study is to assess the efficacy and tolerability of a dual-product regimen MFM and MEC as a treatment in improving intrinsically and extrinsically aged facial and periorbital skin.
Method: Forty-two female subjects, 42 to 65 years, Fitzpatrick skin type I–VI, with mild to moderate droopy eyelids, moderate crow’s feet wrinkles, and moderate global photodamage completed this institutional review board (IRB)-approved study. Subjects applied the MFM and MEC twice-daily for 12 weeks. Clinical grading of efficacy and tolerability parameters, VISIA®-CR imaging, image analysis of wrinkles, skin pH, Tewameter, and pinch recoil measurements were performed at baseline, weeks 4, 8, and 12. Optical coherence tomography (OCT) imaging was performed at baseline and week 12.
Results: Statistically significant improvement was shown in both clinically graded parameters and bio-instrumentational analyses at all time points. Both products were well tolerated by subjects.
Conclusion: This IRB-approved clinical study demonstrated effectiveness in improving intrinsic and extrinsic signs of the global face and periorbital eye area aging after twelve weeks of twice-daily application.
J Drugs Dermatol. 2021;20(12):1314-1321. doi:10.36849/JDD.6355
Aging of upper arm skin, induced by intrinsic and extrinsic factors, often results in a loss of contour, elasticity, and firmness, and an increase in laxity, crepiness, roughness, and photodamage. A topical body firming moisturizer (TBFM) was developed to target all aspects of skin aging.
The aim of this study was to evaluate the efficacy and tolerability of the TBFM for upper arm firming and rejuvenation.
Forty female subjects, 40 to 60 years old, Fitzpatrick skin type II to V, with mild to moderate laxity, crepiness, and photodamage on the upper arms, were recruited into the study, 10 of whom were selected for biopsy analysis. Subjects were randomly allocated to apply the TBFM and placebo moisturizer on the assigned arms twice daily for 12 weeks. At each visit, efficacy and tolerability evaluation, self-assessment, and standardized clinical photography were performed. Ultrasound measurements were performed at baseline, week 8 and week 12.
Efficacy evaluation by a clinical grader and bioinstrumentation analysis showed the TBFM improved all skin parameters of the aged upper arm while outperforming the placebo moisturizer after 12 weeks. Clinical photography showed the test product toned and firmed the skin. The TBFM was well tolerated and well perceived by the subjects. Ultrasound images indicated an improvement in skin density and skin structure at week 12.
This clinical trial indicates that the TBFM was well tolerated and was effective in improving crepey, lax, and photodamaged skin of the upper arms after 12 weeks of treatment twice daily.
Clinical Trial ID: NCT0454597
BACKGROUND: Mimetic wrinkles, commonly referred to as expression lines, form perpendicular to anatomical regions subjected to repeated facial muscle contraction. Neuromodulating peptides have biological activity and can offer a solution to those concerned with expression lines and facial aging. OBJECTIVE: The objective of this randomized, double-blind, placebo-controlled study was to assess the efficacy and tolerability of a line-targeting peptide serum (LTPS) as a stand-alone treatment in improving expression lines and skin health. METHODS: This was an institutional review board-approved study involving healthy subjects. Fifty-five female subjects, 35 to 60 years old, Fitzpatrick Skin Type I to VI, with mild to moderate global face fine lines and wrinkles were recruited. Subjects were randomized to apply LTPS or a placebo serum to their face twice daily for twelve weeks. Short-term efficacy was assessed after fifteen minutes of serum application at baseline. Long-term efficacy and tolerability, self-assessment questionnaire, and VISIA® clinical photography were performed at baseline, Weeks 4, 8, and 12. 3D PRIMOS CR imaging and wrinkle analysis were obtained at baseline and Weeks 8 and 12. RESULTS: The LTPS significantly improved expression lines at fifteen minutes (short term), Weeks 4, 8, and 12 (long term) when compared to the placebo serum as evaluated by a board-certified dermatologist. The LTPS significantly outperformed the placebo serum in improving skin parameters at all time points. VISIA and PRIMOS CR wrinkle analysis substantiated the LTPS’s efficacy. LTPS was well-perceived and well tolerated by the subjects. CONCLUSION: This IRB-approved clinical study demonstrated that LTPS was effective in improving expression lines, wrinkles, and skin health after twelve weeks of application.
Fatigued skin, defined as dehydrated skin with lack of visual facial firmness and dull appearance, can be attributed to intrinsic and extrinsic factors of aging. An anti-aging daily serum (AADS) containing a unique sunflower sprout extract (SSE) was formulated to target fatigued and photodamaged skin.
Utilizing both preclinical and clinical testing models, the efficacy of the AADS was investigated to improve fatigued and photodamaged skin.
Preclinical studies included in vitro analysis of adenosine triphosphate (ATP) production in fatigued dermal fibroblasts, inhibition of ultraviolet radiation A (UVA) induced advanced glycation end products (AGEs) in keratinocytes, and ex vivo gene expression after incubation with the SSE. An institutional review board (IRB)-approved short-term, 7-day, clinical case study was conducted on 28 female subjects, Fitzpatrick skin type I–IV, aged 30–60 years with moderate overall photodamage and skin fatigue. This was a double-blinded, randomized, controlled, single-center case study testing the AADS alone and in combination with an anti-aging facial moisturizer (AAFM).
The SSE boosted intracellular ATP production in fatigued fibroblasts and reduced the formation of AGEs in keratinocytes. The SSE increased expression of genes related to epidermal keratinization and downregulated genes related to inflammation. Statistically significant improvement was found after 7 days of twice-daily use of the AADS alone and in combination with the AAFM. Products were well tolerated and perceived by subjects.
Preclinical results combined with the clinical results strongly suggest that the AADS containing the SSE was tolerable and effective in targeting fatigued and photodamaged skin.
